Dyslipoproteinemia and Impairment of Renal Function in Diabetic Kidney Disease: an Analysis of Animal Studies, Observational Studies, and Clinical Trials

Overview

Journal Rev Diabet Stud

Specialty Endocrinology

Date 2014 Jan 1

PMID 24380087

Citations 13

Authors

Chi-Chih Hung

Jer-Chia Tsai

Hung-Tien Kuo

Jer-Ming Chang

Shang-Jyh Hwang

Hung-Chun Chen

Affiliations

Soon will be listed here.

Abstract

Dyslipoproteinemia is highly prevalent in diabetes, chronic kidney disease, and diabetic kidney disease (DKD). Both diabetes and chronic kidney disease (CKD) are associated with hypertriglyceridemia, lower high-density lipoprotein, and higher small, dense low-density lipoprotein. A number of observational studies have reported that dyslipidemia may be associated with albuminuria, renal function impairment, and end-stage renal disease (ESRD) in the general population, and especially in CKD and DKD patients. Diabetic glomerulopathy and the related albuminuria are the main manifestations of DKD. Numerous animal studies support the finding that glomerular atherosclerosis is the main mechanism of glomerulosclerosis in CKD and DKD. Some randomized, controlled trials suggest the use of statins for the prevention of albuminuria and renal function impairment in CKD and DKD patients. However, a large clinical study, the Study of Heart and Renal Protection (SHARP), does not support that statins could reduce ESRD in CKD. In this article, we analyze the complex association of dyslipoproteinemia with DKD and deduce its relevance from animal studies, observational studies, and clinical trials. We show that special subgroups could benefit from the statin treatment.

Citing Articles

Advances of Iron and Ferroptosis in Diabetic Kidney Disease.

Chu J, Wang K, Lu L, Zhao H, Hu J, Xiao W Kidney Int Rep. 2024; 9(7):1972-1985.

PMID: 39081773 PMC: 11284386. DOI: 10.1016/j.ekir.2024.04.012.

Estimated small dense low-density lipoprotein-cholesterol and the risk of kidney and cardiovascular outcomes in diabetic kidney disease.

Yang Q, Zou Y, Lang Y, Yang J, Wu Y, Xiao X Ren Fail. 2024; 46(2):2369701.

PMID: 38952279 PMC: 467091. DOI: 10.1080/0886022X.2024.2369701.

Association between lipoprotein(a) plasma levels and diabetic nephropathy in Han Chinese patients with type 2 diabetes mellitus.

Wang T PLoS One. 2024; 19(5):e0299240.

PMID: 38743736 PMC: 11093325. DOI: 10.1371/journal.pone.0299240.

Association of Apolipoprotein E Gene Polymorphism with Type 2 Diabetic Nephropathy in the Southern Chinese Population.

Gan C, Zhang Y, Zhang X, Huang Q, Guo X Int J Gen Med. 2023; 16:5549-5558.

PMID: 38034901 PMC: 10683650. DOI: 10.2147/IJGM.S440103.

Serum Lipoprotein(a) and High-Density Lipoprotein Cholesterol Associate with Diabetic Nephropathy: Evidence from Machine Learning Perspectives.

Gao R, Liu B, Yang Y, Ran R, Zhou Y, Liu S Diabetes Metab Syndr Obes. 2023; 16:1847-1858.

PMID: 37378072 PMC: 10292662. DOI: 10.2147/DMSO.S409410.

References

Hunsicker L, Adler S, Caggiula A, England B, Greene T, Kusek J . Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int. 1997; 51(6):1908-19. DOI: 10.1038/ki.1997.260. View

Hsu C, Iribarren C, McCulloch C, Darbinian J, Go A . Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med. 2009; 169(4):342-50. PMC: 2727643. DOI: 10.1001/archinternmed.2008.605. View

KIMMELSTIEL P, Wilson C . Intercapillary Lesions in the Glomeruli of the Kidney. Am J Pathol. 2009; 12(1):83-98.7. PMC: 1911022. View

Scheuer H, Gwinner W, Hohbach J, Grone E, Brandes R, Malle E . Oxidant stress in hyperlipidemia-induced renal damage. Am J Physiol Renal Physiol. 2000; 278(1):F63-74. DOI: 10.1152/ajprenal.2000.278.1.F63. View

Olsen S, Mogensen C . How often is NIDDM complicated with non-diabetic renal disease? An analysis of renal biopsies and the literature. Diabetologia. 1996; 39(12):1638-45. DOI: 10.1007/s001250050628. View

Guijarro C, Kasiske B, Kim Y, ODonnell M, Lee H, Keane W . Early glomerular changes in rats with dietary-induced hypercholesterolemia. Am J Kidney Dis. 1995; 26(1):152-61. DOI: 10.1016/0272-6386(95)90169-8. View

Lee H, Lee J, Koh H, KO K . Intraglomerular lipid deposition in routine biopsies. Clin Nephrol. 1991; 36(2):67-75. View

Kramer H, Nguyen Q, Curhan G, Hsu C . Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA. 2003; 289(24):3273-7. DOI: 10.1001/jama.289.24.3273. View

Molitch M, DeFronzo R, Franz M, Keane W, Mogensen C, Parving H . Nephropathy in diabetes. Diabetes Care. 2003; 27 Suppl 1:S79-83. DOI: 10.2337/diacare.27.2007.s79. View

10.

Muntner P, Coresh J, Smith J, Eckfeldt J, Klag M . Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int. 2000; 58(1):293-301. DOI: 10.1046/j.1523-1755.2000.00165.x. View

11.

Dalrymple L, Kaysen G . The effect of lipoproteins on the development and progression of renal disease. Am J Nephrol. 2008; 28(5):723-31. DOI: 10.1159/000127980. View

12.

Liberopoulos E, Siamopoulos K, Elisaf M . Apolipoprotein E and renal disease. Am J Kidney Dis. 2004; 43(2):223-33. DOI: 10.1053/j.ajkd.2003.10.013. View

13.

Suzaki K, Kobori S, Ueno S, Uehara M, KAYASHIMA T, Takeda H . Effects of plasmapheresis on familial type III hyperlipoproteinemia associated with glomerular lipidosis, nephrotic syndrome and diabetes mellitus. Atherosclerosis. 1990; 80(3):181-9. DOI: 10.1016/0021-9150(90)90025-e. View

14.

Zimmet P, Alberti K, Shaw J . Global and societal implications of the diabetes epidemic. Nature. 2001; 414(6865):782-7. DOI: 10.1038/414782a. View

15.

Jun M, Zhu B, Tonelli M, Jardine M, Patel A, Neal B . Effects of fibrates in kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol. 2012; 60(20):2061-71. DOI: 10.1016/j.jacc.2012.07.049. View

16.

Slinin Y, Ishani A, Rector T, Fitzgerald P, MacDonald R, Tacklind J . Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI clinical practice guideline. Am J Kidney Dis. 2012; 60(5):747-69. DOI: 10.1053/j.ajkd.2012.07.017. View

17.

Chen H, Guh J, Shin S, Lai Y . Pravastatin suppress superoxide and fibronectin production of glomerular mesangial cells induced by oxidized-LDL and high glucose. Atherosclerosis. 2002; 160(1):141-6. DOI: 10.1016/s0021-9150(01)00545-7. View

18.

Tonelli M, Collins D, Robins S, Bloomfield H, Curhan G . Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease. Am J Kidney Dis. 2004; 44(5):832-9. View

19.

Kasiske B, ODonnell M, Schmitz P, Kim Y, Keane W . Renal injury of diet-induced hypercholesterolemia in rats. Kidney Int. 1990; 37(3):880-91. DOI: 10.1038/ki.1990.62. View

20.

Valmadrid C, Klein R, Moss S, Klein B . The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med. 2000; 160(8):1093-100. DOI: 10.1001/archinte.160.8.1093. View